Head-To-Head Analysis: ANI Pharmaceuticals (NASDAQ:ANIP) and IM Cannabis (NASDAQ:IMCC)

IM Cannabis (NASDAQ:IMCC) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Earnings and Valuation

This table compares IM Cannabis and ANI Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.17 million	0.01	-$8.10 million	($60.66)	-0.03
ANI Pharmaceuticals	$978.38 million	1.66	$78.34 million	$4.64	15.24

ANI Pharmaceuticals has higher revenue and earnings than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for IM Cannabis and ANI Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1	0	0	0	1.00
ANI Pharmaceuticals	0	4	5	0	2.56

ANI Pharmaceuticals has a consensus price target of $105.57, indicating a potential upside of 49.34%. Given ANI Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than IM Cannabis.

Profitability

This table compares IM Cannabis and ANI Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	-585.96%	-58.32%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Volatility and Risk

IM Cannabis has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

Summary

ANI Pharmaceuticals beats IM Cannabis on 13 of the 14 factors compared between the two stocks.

About IM Cannabis

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.